<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nosyk B</submitter><funding>Michael Smith Foundation for Health Research</funding><funding>Canadian Institutes for Health Research</funding><pagination>e048353</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8190984</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(6)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>The COVID-19 pandemic was preceded by an ongoing overdose crisis and linked to escalating drug overdose deaths in British Columbia (BC). At the outset of these dual public health emergencies, the BC government announced interim Risk Mitigation Guidance (RMG) that permitted prescribing medication alternatives to substances, including opioids, alcohol, stimulants and benzodiazepines, an intervention sometimes referred to as 'safe supply'. This protocol outlines the approach for a study of the implementation of RMG and its impacts on COVID-19 infection, drug-related and systemic harms, continuity of care for people with substance use disorder (SUD), as well as their behavioural, psychosocial and well-being outcomes.&lt;h4>Methods and analysis&lt;/h4>We conducted a parallel mixe</pubmed_abstract><journal>BMJ open</journal><pubmed_title>Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.</pubmed_title><pmcid>PMC8190984</pmcid><funding_grant_id>18951</funding_grant_id><funding_grant_id>172671</funding_grant_id><pubmed_authors>Slaunwhite A</pubmed_authors><pubmed_authors>Barker B</pubmed_authors><pubmed_authors>Hongdilokkul N</pubmed_authors><pubmed_authors>Zhao B</pubmed_authors><pubmed_authors>Lock K</pubmed_authors><pubmed_authors>Thomson E</pubmed_authors><pubmed_authors>Beck-McGreevy P</pubmed_authors><pubmed_authors>Pauly B</pubmed_authors><pubmed_authors>Card KG</pubmed_authors><pubmed_authors>Palis H</pubmed_authors><pubmed_authors>Min JE</pubmed_authors><pubmed_authors>Urbanoski K</pubmed_authors><pubmed_authors>Meilleur L</pubmed_authors><pubmed_authors>Nosyk B</pubmed_authors><pubmed_authors>Burmeister C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.</name><description>&lt;h4>Introduction&lt;/h4>The COVID-19 pandemic was preceded by an ongoing overdose crisis and linked to escalating drug overdose deaths in British Columbia (BC). At the outset of these dual public health emergencies, the BC government announced interim Risk Mitigation Guidance (RMG) that permitted prescribing medication alternatives to substances, including opioids, alcohol, stimulants and benzodiazepines, an intervention sometimes referred to as 'safe supply'. This protocol outlines the approach for a study of the implementation of RMG and its impacts on COVID-19 infection, drug-related and systemic harms, continuity of care for people with substance use disorder (SUD), as well as their behavioural, psychosocial and well-being outcomes.&lt;h4>Methods and analysis&lt;/h4>We conducted a parallel mixe</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2026-05-09T08:36:53.821Z</modification><creation>2025-06-01T02:32:22.879Z</creation></dates><accession>S-EPMC8190984</accession><cross_references><pubmed>34108170</pubmed><doi>10.1136/bmjopen-2020-048353</doi></cross_references></HashMap>